紫杉类药物新辅助化疗治疗老年乳腺癌的临床效果

扫码查看

原文链接

万方数据
维普

中文摘要：目的:分析紫杉类药物新辅助化疗治疗老年乳腺癌的临床效果。方法:回顾性选取 2020 年 1 月—2022 年 1 月福建医科大学肿瘤临床医学院乳腺外科收治的 71 例老年乳腺癌患者临床资料。根据新辅助化疗药物不同将其分为对照组(35 例)和观察组(36 例)。对照组给予紫杉醇注射液新辅助化疗，观察组给予紫杉醇脂质体新辅助化疗。比较两组临床疗效，不良反应，治疗依从性，治疗前后生活质量。结果:观察组总缓解率略高于对照组，但比较差异无统计学意义(P>0。05)。观察组不良反应发生率低于对照组，差异有统计学意义(P<0。05)。观察组治疗总依从性高于对照组，差异有统计学意义(P<0。05)。治疗后，观察组生理功能、生理职能、躯体疼痛、总体健康、活力、社会功能、情感职能、精神健康评分均高于对照组，差异有统计学意义(P<0。05)。结论:紫杉醇脂质体新辅助化疗的应用，既满足临床疗效需求，同时也最大限度减少了副作用，对减轻患者化疗过程中的痛苦，提高治疗依从性，改善生存质量起到了积极影响。

外文标题：Clinical Effect of Paclitaxel Drugs Neoadjuvant Chemotherapy in the Treatment of Elderly Breast Cancer

外文摘要：Objective:To analyze the clinical effect of Paclitaxel drugs neoadjuvant chemotherapy in the treatment of elderly breast cancer.Method:The data of 71 elderly patients with breast cancer admitted to the Department of Breast Surgery in Fujian Cancer Hospital from January 2020 to January 2022 was retrospectively selected.According to different neoadjuvant chemotherapy drugs,the patients were divided into control group(35 cases)and observation group(36 cases).The control group received neoadjuvant chemotherapy with Paclitaxel Injection,and the observation group received neoadjuvant chemotherapy with Paclitaxel Liposome.The clinical efficacy,adverse reactions,treatment compliance and quality of life before and after treatment were compared between the two groups.Result:The total remission rate of the observation group was slightly higher than that of the control group,but the difference was not statistically significant(P>0.05).The incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).The total treatment compliance of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the scores of physiological function,role physical,physical pain,general health,vitality,social function,emotional function,mental health of the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).Conclusion:The application of Paclitaxel Liposome neoadjuvant chemotherapy not only meets the needs of clinical efficacy,but also minimizes side effects to the greatest extent possible,which has a positive impact on alleviating the pain of patients during chemotherapy,improving treatment compliance,and improving the quality of life.

外文关键词：

Paclitaxel drugsNeoadjuvant chemotherapyElderly breast cancerTotal relief rateAdverse reactionsTreatment complianceQuality of life

作者：

杨灿、黄丽英

展开 >

作者单位：

福建医科大学肿瘤临床医学院(福建省肿瘤医院) 福建福州 350001

关键词：

紫杉类药物新辅助化疗老年乳腺癌总有效率不良反应治疗依从性生活质量

出版年：

2024

DOI：